Results 221 to 230 of about 332,163 (305)

Lung Adenocarcinoma Promotes NETosis via the NPM1-TNFAIP6-CD44-SPP1 Axis. [PDF]

Cancers (Basel)
Liu R, Hu Z, Li M, Yang S, Wang J, Zhang Z, Yang L, Chen J.   +7 more
europepmc   +1 more source

ERO1A as a novel biomarker for risk stratification and immunotherapeutic guidance in early-stage lung adenocarcinoma. [PDF]

PeerJ
Chen W, Li H, Zeng J, Xie G, Chen Z, Xu X, Bai W, Xiao G, Xie J.   +8 more
europepmc   +1 more source

Lung adenocarcinoma

, 2017
openaire   +1 more source

Multi-Omics Analysis of TYMS as a Prognostic Biomarker and Therapeutic Target for Lung Adenocarcinoma. [PDF]

Cancer Med
Shi H, Zhang P, Chen J, Li H, Zhang X, Zeng B, Liu T, Zeng T.   +7 more
europepmc   +1 more source

Impact of particulate matter 2.5 on a mouse model of lung adenocarcinoma. [PDF]

BMC Pulm Med
Bektas EI, Alam A, Senchanthisai S, Mayengbam SS, Mackey E, Spitz E, Alam S, Atanassov B, Goodrich DW, Dey P.   +9 more
europepmc   +1 more source

A dose‐finding population pharmacokinetic/pharmacodynamic model of ginisortamab, an anti‐gremlin‐1 monoclonal antibody, in patients with solid tumours

British Journal of Clinical Pharmacology, EarlyView.
Aims Ginisortamab, a first‐in‐class human monoclonal antibody for the treatment of advanced solid tumours, binds to gremlin‐1 and restores bone morphogenetic protein signalling. We used pharmacokinetic/pharmacodynamic (PK/PD) modelling to characterize the relationship between ginisortamab dose and serum gremlin‐1 binding, using model‐based simulations ...
Yin Cheong Wong, Luisa Rojas Chavarro, Paul Jones, David Egging, Wanchana Ungphakorn, Marta Valle, Ivan Matthews   +6 more
wiley   +1 more source

CircSMAD4 shapes matrix-remodeling TAMs in lung adenocarcinoma. [PDF]

Noncoding RNA Res
Yu Z, Wang X, Zheng Y, He Y, Lin J, Xiao Y, Mo B, Xie H, Hang S, Gao X, Xu P, Liu Y, Xiao H.   +12 more
europepmc   +1 more source